NCT03585946View on ClinicalTrials.gov

Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis

Not yet recruitingOBSERVATIONAL

Enrollment

750

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions

Stevens-Johnson SyndromeToxic Epidermal NecrolysisDrug Reaction

Interventions

DRUG

Site specific standard of care comparison

Patients outcomes will be assessed and compared based on the medication they receive which will be assigned based on the standard of care at each enrolling site.

All Listed Sponsors

lead

Massachusetts General Hospital

OTHER

NCT03585946 - Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis | Biotech Hunter | Biotech Hunter